The Economist. New data presented at United European Gastroenterology (UEG) Week 2016 reveal that switching from parent inflliximab to infliximab biosimilar (CT-P13) is non-inferior to continued parent drug treatment and that patients can switch with complete security.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
